Viridian Therapeutics Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors of the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 173,000 shares of the Company’s common stock to five new employees (the “Incentive Grants”) on September 3, 2024 (the “Grant Date”). The Incentive Grants were granted outside of the Company’s Amended and Restated 2016 Stock Incentive Plan (the “Plan”), but remain subject to the terms of that Plan. The Incentive Grants were granted to these individuals as an inducement to enter into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).

The incentive awards have an exercise price per share equal to the closing price of Viridian common stock on the grant date. The incentive awards vest over a four-year period, with 25% of the shares vesting on the first anniversary of the employee’s employment and the remaining shares vesting thereafter in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the respective vesting dates.